Session Information
Date: Tuesday, June 21, 2016
Session Title: Myoclonus
Session Time: 12:30pm-2:00pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To evaluate the long-term effect of botulinum toxin type A (BTX-A) in the treatment of hemifacial spasm (HFS) in a large group of patients from south of Brazil.
Background: Hemifacial spasm (HFS) is a craniofacial movement disorder characterized by involuntary contractions of the muscles on one side of the face. Botulinum toxin type A (BTX-A) has been used to treat HFS since the 1980s and provides symptom relief and improved quality of life in about 85% to 95% of cases.
Methods: A retrospective analysis of patients treated at the Movement Disorders Outpatient Unit in the Neurology Service, Hospital de Clínicas, Federal University of Paraná, Curitiba, from 2009 to 2013 was carried out. In all, 550 BTX injections were administered to 100 patients with HFS, by Neurology Residents (R3, R4) and Fellows.
Results: Mean duration of improvement following each injection session was 3.14 months, mean latency 7.10 days and mean success rate 94.73%. Patients were evaluated by a physician at an interval of 5.76 months after each application. Adverse effects, which were mostly minor, were observed in 37% of the patients at least once during follow-up. The most frequent was ptosis (35.14%).
Conclusions: Treatment of HFS with BTX-A was effective, sustainable and safe and had minimal, well-tolerated side effects.
To cite this abstract in AMA style:
H.A.G. Teive, J.P. Matisti, A.D. Kleinfelder, N.B. Galli. Hemifacial spasm – Therapeutic assessment of botulinum toxin [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/hemifacial-spasm-therapeutic-assessment-of-botulinum-toxin/. Accessed June 14, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/hemifacial-spasm-therapeutic-assessment-of-botulinum-toxin/